ESR1 and breast cancer: Bortezomib, an FDA approved proteasome inhibitor has been shown to inhibit multiple genes associated with poor prognosis in ERα breast cancer (46), however several clinical studies have shown contradictory results in advanced/metastatic breast cancer (47–49).